A new method makes it possible to attach cancer-killing drugs to antibodies at a precise location using a process that can be completed in just two steps, potentially making targeted cancer medicines easier to develop and manufacture.

Antibody-drug conjugates have become an important new class of cancer medicines. These drugs combine an antibody, which finds cancer cells, with a powerful cancer-killing drug. The antibody delivers the drug to the tumor, allowing treatment to be concentrated where it is needed.

But making these medicines can be complex. A single batch of an antibody-drug conjugate can contain molecules with the drug attached at different locations and in different amounts. This can make the medicine harder to characterize, manufacture and control.

A new study describes a simpler way to make these drugs more precisely. The method attaches the cancer-killing drug to the same location on each antibody, creating a more uniform product. It also dramatically simplifies one of the most difficult parts of the process: preparing the chemical material needed to attach the drug. The resulting antibody-drug conjugates successfully killed cancer cells in laboratory studies and slowed tumor growth in mice, while showing little effect on cells that lacked the cancer target.

Making Every Antibody the Same

An antibody-drug conjugate has two main parts: the antibody recognizes a protein on a cancer cell, and the attached drug then kills the cell. The challenge is deciding where and how many drug molecules should be attached to the antibody. Traditional methods produce a mixture of different versions. Some antibodies may carry more drugs than others, and the drugs may attach at different locations.

However, a more uniform medicine is easier to study and manufacture, and it can behave more predictably in the body. The new method takes advantage of a natural sugar structure found on antibodies. This structure sits at the same location on essentially every antibody of the same type.

By modifying this site, the researchers were able to attach a drug to a consistent location on the antibody. The result is a more uniform antibody-drug conjugate, with the drug attached in a controlled way rather than at random locations.

Previous methods for this type of antibody engineering often require extensive steps to prepare the material needed to modify the antibody. Some approaches also require several different enzymes. The new method uses a modified form of a naturally occurring sugar that can be prepared in as few as two steps from commercially available materials. That difference could matter well beyond the laboratory as a process that requires fewer steps is easier to reproduce, scale up and potentially incorporate into drug manufacturing.

The modified sugar can then be attached to the antibody using a single enzyme. Once the sugar is in place, it provides a chemical “handle” that allows the cancer-killing drug to be attached. The approach therefore addresses two problems at once: it makes the final antibody drug more uniform while simplifying the manufacturing process.

Putting the Method to the Test

The researchers used the cancer drug trastuzumab as the antibody component. Trastuzumab recognizes a protein found at high levels on some cancer cells. The resulting antibody-drug conjugates were tested against cancer cells with and without the protein. The drugs strongly killed cancer cells with the protein but had little effect on cells without it.

The treatment also worked in mice carrying human tumors. The antibody-drug conjugate significantly slowed tumor growth, without causing significant weight loss or other obvious signs of toxicity at the tested dose. These results show that simplifying the antibody-making process did not come at the cost of its ability to target and kill cancer cells.

More Than One Type of Cancer Drug

The method may also extend beyond conventional antibody-drug conjugates. The same antibody engineering strategy was used to create an antibody linked to a different type of cancer drug that works by destroying a cancer-driving protein inside the cell. This second approach also showed greater activity against cancer cells carrying the protein target.

The method was also successfully transferred to several different antibodies, suggesting that it is not limited to a single cancer drug or antibody. That flexibility could make the technology useful as more types of antibody-based medicines are developed.

A More Practical Path to Targeted Medicines

Targeted cancer drugs increasingly depend on sophisticated combinations of antibodies and powerful drugs. As these therapies become more complex, the ability to manufacture them in a controlled way becomes increasingly important.

The new method offers a simpler route. It can prepare the key material in just two steps, use a single enzyme to modify the antibody and produce a uniform drug with the cancer-killing compound attached at a defined location. By making antibody conjugates easier to build and more consistent, this approach could help accelerate the development of the next generation of targeted cancer treatments.